Mineralys Therapeutics (MLYS) Enterprise Value (2022 - 2026)

Mineralys Therapeutics (MLYS) has 5 years of Enterprise Value data on file, last reported at -$644.9 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 88.02% year-over-year to -$644.9 million; the trailing twelve-month figure through Mar 2026 stood at -$644.9 million (down 88.02% YoY), and the FY2025 full-year result was -$656.6 million, down 231.32% from the prior year.
• Enterprise Value climbed to -$644.9 million in Q1 2026, from -$656.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$110.1 million in Q4 2022 to a low of -$656.6 million in Q4 2025.
• A 5-year average of -$342.4 million and a median of -$289.4 million in 2023 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value grew 16.22% in 2024 and tumbled 231.32% in 2025, its largest moves.
• Tracing MLYS's Enterprise Value over 5 years: stood at -$110.1 million in 2022, then sank by 114.85% to -$236.6 million in 2023, then gained by 16.22% to -$198.2 million in 2024, then plunged by 231.32% to -$656.6 million in 2025, then climbed by 1.78% to -$644.9 million in 2026.
• Business Quant data shows MLYS's Enterprise Value at -$644.9 million in Q1 2026, -$656.6 million in Q4 2025, and -$593.6 million in Q3 2025.